New Special Examines Living With Alzheimer's
TV anchor Bill Ritter details his early-stage Alzheimer's diagnosis and current treatment options.
Updated on Oct. 21, 2026 in Alzheimer’s
Longtime New York television anchor Bill Ritter recently shared his experience with early-stage Alzheimer's disease through a new half-hour special, Living With Alzheimer's. The program highlights the realities of living with the condition and covers current treatment landscapes for others navigating a diagnosis.
Why it matters
The special offers insight into how individuals manage early-stage Alzheimer's and provides an overview of the evolving treatment options available for the condition. It underscores the importance of staying informed about emerging research and clinical developments in neurodegenerative care.
Clinical trial results indicate that FDA-approved medications lecanemab and donanemab slow cognitive decline. Further research is ongoing as new generations of treatments continue to undergo testing and approval.
The players
Bill Ritter
A 76-year-old television anchor who spent 28 years in New York local media and recently shared his early-stage Alzheimer's diagnosis.
WABC-TV
The New York television station that broadcast the special program on Alzheimer's disease.
The details
The program features interviews with medical researchers and individuals living with Alzheimer's to explore the daily management of the disease. It also discusses the role of recently approved medications, which work to address the underlying progression of the condition. By documenting his own journey, Ritter aims to provide a clear look at navigating cognitive changes while highlighting the current standard of care.
Timeline
June 2026: Bill Ritter was diagnosed with early-stage Alzheimer's disease.
June 12, 2026: Ritter publicly announced his diagnosis.
October 15, 2026: The special program Living With Alzheimer's aired on WABC-TV.
Health Landscape
This report sits within a rapidly shifting treatment landscape defined by the recent FDA approval of therapies like lecanemab and donanemab. It highlights the growing focus on early intervention and the importance of clinical research as new treatment generations enter the pipeline.
Understanding the current options for slowing cognitive decline is essential for those recently diagnosed or concerned about memory changes. These developments are best discussed with a physician to evaluate whether current clinical therapies are appropriate for your specific health needs.
The takeaway
Early-stage Alzheimer's management requires staying current with rapidly evolving clinical research and treatment protocols. Discuss any persistent concerns regarding cognitive health with your doctor to stay informed about the latest care and research developments.
Further reading
For more information on the progression and management of the condition, visit our Alzheimer’s section.
Source note: This article includes information reported by MediaPost.
